Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference

CHICAGO--(BUSINESS WIRE)-- Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that CEO Matthias Schroff will provide a virtual presentation at the 2022 H.C. Wainwright Global Life Sciences Conference, occurring May 23-26, 2022.

The presentation will be available for on-demand viewing beginning May 24, 2022 at 7:00AM EST via the virtual conference link, and will be archived for 90 days.

Exicure will be taking 1x1 investor meetings with registered conference attendees.

About Exicure

Exicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. The team includes a diverse scientific group with expertise in nucleic acid chemistry, drug development and neuroscience. Headquartered in Chicago, Illinois, the Company conducts its discovery and development efforts in-house with a dedicated 30,000 square foot facility, including rapid and automated high throughput nucleic acid synthesis and screening. For further information, see www.exicuretx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005381/en/

Karen Sharma

MacDougall

781-235-3060

ksharma@macdougall.bio

Source: Exicure, Inc.